IMBiologics
PublicIMBiologics is now publicly traded
The data on this page reflects IMBiologics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Jul 24, 2023
Total Funding Raised
$19.14M
Company Overview
IMBiologics is a biotechnology company that develops immunomodulatory antibody therapeutics for the treatment of autoimmune diseases and cancer.
AI Layer
Non-AI
Keywords
biotechnologyantibody therapeuticsbispecific antibodyautoimmune diseasedrug discoverybiologicsfusion proteinclinical developmentinflammatory diseasebiotech R&Ddrug licensingbiotech startuppharma pipelinepreclinical research
IMBiologics Comparables
Compare IMBiologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Navigator Medicines | 88% | |
| Lmito Therapeutics | 65% | |
| ImmunAbs Inc. | 64% |
IMBiologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 24, 2023 | ||||
| Seed | Jan 19, 2021 |
IMBiologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Shinhan Venture Investment | Series B |
| Kingo Investment Partners | Series B |
| KB Investment | Series B, Seed |
| Ard Partners | Series B |
| Woori Financial Group | Series B |
| Yuanta Securities | Series B |
IMBiologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFirmographic Details
Headquarters—
Employee Range6
Year Founded2020
Last FundingJul 24, 2023
See something wrong or outdated?